4,971 Shares of Thermo Fisher Scientific Inc. $TMO Bought by Trek Financial LLC

Trek Financial LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,971 shares of the medical research company’s stock, valued at approximately $3,356,000.

Other hedge funds also recently bought and sold shares of the company. Polaris Financial Partners acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $32,000. Laurel Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $32,000. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $25,000. Legacy Wealth Managment LLC ID increased its holdings in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Finally, Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth $26,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $723.00 to $756.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. CLSA started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price target for the company. Finally, DZ Bank lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $689.10.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 76,199 shares of company stock valued at $45,896,780 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 2.1%

Shares of TMO opened at $682.43 on Tuesday. The stock has a 50 day moving average price of $655.94 and a 200 day moving average price of $553.32. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $711.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $252.33 billion, a price-to-earnings ratio of 35.99, a PEG ratio of 2.87 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the firm posted $5.79 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.